European Innovation Council

C2C NewCap, founded in 2014 by Rui Silva and Andre Mao de Ferro, is a Lisbon-based manufacturer specializing in the production of supercapacitors designed for efficient electrical energy storage. The company focuses on developing next-generation devices that utilize proprietary electrodes and an aqueous electrolyte, which contribute to a low environmental impact. C2C NewCap aims to provide clients with energy storage solutions that not only enhance operational efficiency but also reduce overall environmental and operational costs.

C2C NewCap, founded in 2014 by Rui Silva and Andre Mao de Ferro, is a Lisbon-based manufacturer specializing in the production of supercapacitors designed for efficient electrical energy storage. The company focuses on developing next-generation devices that utilize proprietary electrodes and an aqueous electrolyte, which contribute to a low environmental impact. C2C NewCap aims to provide clients with energy storage solutions that not only enhance operational efficiency but also reduce overall environmental and operational costs.

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, focused on developing innovative diagnostic products and services for liver cancer. Established in 2015, Ophiomics integrates bioinformatics, genomics, and artificial intelligence to enhance the diagnostic and prognostic capabilities in oncology. The company specializes in creating biomarker-based diagnostic devices that utilize molecular signatures combined with clinical parameters in predictive algorithms, facilitating early detection of hepatocellular carcinoma. With a commitment to quality, Ophiomics holds ISO 13485 and ISO 9001 certifications and boasts a diverse pipeline of products at various stages of development, from pre-clinical programs to those undergoing clinical validation.

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, focused on developing innovative diagnostic products and services for liver cancer. Established in 2015, Ophiomics integrates bioinformatics, genomics, and artificial intelligence to enhance the diagnostic and prognostic capabilities in oncology. The company specializes in creating biomarker-based diagnostic devices that utilize molecular signatures combined with clinical parameters in predictive algorithms, facilitating early detection of hepatocellular carcinoma. With a commitment to quality, Ophiomics holds ISO 13485 and ISO 9001 certifications and boasts a diverse pipeline of products at various stages of development, from pre-clinical programs to those undergoing clinical validation.